Aileron Therapeutics, Inc.ALRNNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank50
3Y CAGR-11.7%
5Y CAGR+2.0%
Year-over-Year Change
Research and development spending
3Y CAGR
-11.7%/yr
vs -0.7%/yr prior
5Y CAGR
+2.0%/yr
Recent deceleration
Acceleration
-11.1pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $12.35M | -13.3% |
| 2024 | $14.25M | +257.0% |
| 2023 | $3.99M | -77.8% |
| 2022 | $17.97M | +5.6% |
| 2021 | $17.01M | +52.3% |
| 2020 | $11.17M | -36.8% |
| 2019 | $17.66M | -4.3% |
| 2018 | $18.45M | +29.6% |
| 2017 | $14.24M | +38.6% |
| 2016 | $10.28M | - |